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PATENTING OF RESEARCH TOOLS -

ISSUES

AND

SOVIE POINTERS
Zakir Thomas'

This paper presents a comprehensive analysis of the patenting of research
tools. It outlines the essentials of research tools and addresses the concerns
that have croppedup in the post-Genomic erawith a special emphasis on the
issue of access. Itfurtherevaluates the issuefrom a legal perspectiveagainst
the backdrop of the TRIPS Agreement and makes a comparative analysis
between jurisdictions.It also gives an overview of the possible consequences
ofsuch patentingfor India and concludes by recommendingamendments to
tackle the challenges raised.
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Writing in Science, in the December of 1968, Garret Hardin introduced the
metaphor 'Tragedy of the Commons', to analyse concerns of overpopulation, air
pollution and species extinction.' Ever since, this metaphor has been used to
describe situations where people overuse resources because they have no incentive
to conserve them. Thirty years later, writing in Science, on patents, and referring
to Hardin, Michael Heller and Rebecca Eisenberg suggested a different tragedy,
an anti commons, in which people underuse scarce resources because too many
owners block each other. The research tool patents were at the core of their
argument.
*

1.

The author is an I.R.S. officer and former Registrar of Copyrights. He is a Master in
Intellectual Property from the Franklin Pierce Law Centre, US. Views expressed are
personal. The author is grateful to Ms. Simi George for her excellent research support.
G. Hardin, The Tragedy of the Commons, 162 ScIENcE 1243 (1968). Hardin postulated
that the population problem fell into a class of problems which could be classified as
"no technical solution problems". Talking about the population problem, he urged
that the most important necessity of the times was to restrict the freedom to abandon

breeding in order to restrict the population problem.
2.

M.A. Heller & R.S. Eisenberg, Can Patents Deter Innovation? The Anti Commons in
Biomedical Research, 280 ScIrNce 698 (1988).
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TRIPS is now a fact of history. All developing and developed countries
have the common minimum standards of Intellectual Property protection
mandated in TRIPS, ensured through the mechanism of Dispute Settlement, and
the TRIPS Council Reviews. In the post-TRIPS globalised era, countries at
different stages of development can learn from the way the challenges created
by intellectual property rights have been addressed by nations who had faced
these challenges earlier.
A decade has passed since the anti commons tragedy was suggested, and it
is time to look at how this issue has been addressed by various stakeholders. During
this time, India has forged ahead as a fast growing economy, The Government of
India is proposing to create a legal framework for government funded research,
and grant universities and research institutions ownership and patent rights for
their innovations, along the lines of the Bayh-Dole Act of the United States? Hence,
the United States experience will be increasingly relevant for India.
The purpose of this paper is to annotate the issues reported on the patenting
of research tools and analyse the responses from a legal, policy and management
perspective, and its consequences for India. Part A of this paper explains what
research tools are and the concerns relating to access to them. Part B deals with
the legal landscape and Part C gives an overview of some practical responses, as
well as of the legal challenges involved. The article concludes by suggesting changes
in the law, as well as the adoption of appropriate management strategies.

I. PART A
A. Research Tools
"Research tool" is a generic term, and refers to a range of resources that
scientists use in the laboratory for conducting further experiments. 4 They may be
broadly described as any tangible or informational input required in the process
of discovering a drug, a medical therapy, a diagnostic method, or a new crop

3.
4.

K. Pathak, Varsities May Soon Own Patent Rights, BusaNss STANDARD (Mar. 17, 2008).
The definition of "research tools" is necessarily broad, and it is acknowledged that
the same material can have different uses, being a research tool in some contexts and
a product in others. The National Institute of Health (NIH) in the United States has
given some guidelines in determining how an NIH-funded resource that falls within
the definition should be handled. Recipients should determine whether:
1) the primary usefulness of the resource is as a tool for discovery rather than an
FDA-approved product or integral component of such a product;
182

Patentingof Research Tools -Issues and Some Pointers
variety5 Research tools commonly include cell lines, monoclonal antibodies,
reagents, animal models, growth factors, nucleic acid and proteins, combinational
chemistry libraries, proteomic libraries, drugs and drug targets, clones and cloning
tools, expression and reporter systems, and databases, software, laboratory
equipment and machines.'
The effect of patenting on access to research tools will vary Research tool

patents are "upstream" technology, used in the research process itself. Patents are
unlikely to interfere with access to research tools like chemical reagents that are
readily available in the market at reasonable prices from patent holders (or
licensees), through catalogues, under conditions that approach an anonymous
market.8 Some other research tools can be obtained only by approaching the patent
holder directly and negotiating license conditions, or on onerous license conditions.
In such cases, patents pose a threat to researchers 9
The following case studies cited by the United States National Institute of
Health (NIH) demonstrate how license conditions impact access to research tools."
The three technologies discussed below have three different licensing paradigms.

2) the resource is a broad, enabling invention that will be useful to many scientists (or
multiple companies in developing multiple products), rather than a project or product-

specific resource; and
3) the resource is readily useable or distributable as a tool, rather than the situation
where private sector involvement is necessary or the most expedient means for
developing or distributing the resource. Recipients of NIH funding should ensure
that their intellectual property strategy for resources fitting one or more of the above
criteria enhances, rather than restricts, the ultimate availability of the resource. If the
recipient believes private sector involvement is desirable to achieve this goal, the
recipient should strategically license the invention under terms commensurate with
the goal. See http://ott.od.nih.gov/policy/rt-guidejfinal.html.
5.

C. Clift, Patentingand Licensing Research Tools, in INTELLECTUAL PROPERTY MANAGEMENT

6.

iN HEALTH AND AIucuurtURAL INNOVATION: A HANDBOOK OF BEST PRACHCES (A. Krattiger
et al. eds., 2007).
Report of the NIH Working Group on Research Tools, available at www.nih.gov; see

7.

also R.K. Seide and M.M. LeCointe, Research Tool Patents: Are there any Exceptions to
Infringement?, available at http://www7.nationalacademies.org/step/
Seide-presentation augustproteomics.PPT.
Eisenberg, Patenting Research Tools and the Law, in INTELLECIUAL PROPERTY RIGHTS AND
RESEARCH

TOOLS

IN MOLECULAR

8.

Id.

9.

Eisenberg, supra note 7.

BioLOGY (1997).

10. Supra note 6.
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Recombinant DNA technology, known as Cohen-Bayer technology, is the
founding technology of the modern biotechnology industry" Every molecular
biologist uses this tool. The University of Stanford, which is the rights holder of
the Cohen-Bayer patent, made this technology available for researchers with an
inexpensive non-exclusive license with minimal riders. The decision of the
University of Stanford to license this technology through a non-exclusive license,
instead of an exclusive one, is regarded as critical to the development of the
biotechnology industry. 2
Polymerase Chain Reaction (PCR) allows the hitherto impossible - analysis
of genes in biological samples, such as assays of gene expression in individual
cells by specific and rapid amplification of targeted DNA or RNA sequences. PCR
was invented in a corporate environment and originally patented by Cetus
Corporation. Cetus subsequently sold the PCR patent to Hoffman LaRoche for
US$300 million in 1991.' There is general agreement among the scientific
community that Hoffman LaRoche has done well in making the patented
technology available for research purposes. 4 While there was no controversy over
whether such an important research tool should be patented, or over the principle
of charging researchers license fees, there has been some debate over the amount
of royalty fees) 5 For the PCR license, a company pays between US$100,000 and
US$500,000, with a royalty rate of 15%. In contrast, a company pays US$10,000
11. This technology is used to insert foreign genes into bacteria to study the process of

12.

13.
14.
15.

gene replication. It involved three patents: one process patent for making molecular
chimeras and two product patents - one for proteins produced using recombinant
prokaryote DNA, and another for proteins from recombinant eukaryote DNA.
The Cohen-Boyer patent is considered by many to be a classic model of technology
transfer envisaged in the Bayh-Dole Act, which was intended to transfer university
developed technology to the commercial sector. However, it has also been pointed out
that this presents a different model of technology transfer than what is envisaged in the
Bayh-Dole Act. Lita Nelson, Director of Technology at Massachusetts Institute of
Technology, has noted that the premise of Bayh-Dole Act is the maximisation of revenue
through exclusivity while the Cohen Boyer license is a non-exclusive. See supra note 6.
National Research Council (NRC) (1997), Intellectual PropertyRights and Research Tools
in Molecular Biology, availableat www.nap.edu/readingroom/books/property.
Id.
Supra note 13. Roche established different categories of licenses related to PCR,
depending on the application and the users. They included research applications,
such as Human Genome project, the discovery of new genes, the studies of gene
expression; diagnostic application, such as human in-vitro diagnostics, and the
detection of disease linked mutations; the production of large quantities of DNA; and
human diagnostic testing services. The licenses in the last category are the most
expensive, but they are very broad. In 1999, the patent was held invalid for inequitable
conduct. See J.P. Walsh et al, Research Tool Patentingand BiomedicalInnovationin PAmsN
IN KNOWLEDGE BAsrn EcoNomy (2003).
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per year, and a royalty fee of 0.5%-10%, for the Cohen Bayer license. Some argue

that this has resulted in the inhibition of the development of PCR related research
tools. 6
Protein sequencing has been a key step in deciphering gene function, as the
effects of the genes depend on the proteins they encode. Until automated
sequencing instruments became widely available, few laboratories had access to
this technology Automated and highly sensitive DNA and protein sequencers
were developed by the California Institute of Technology (Cal Tech), which was
funded by the private sector firm Applied Biosystems (ABI)." ABI insisted on and
received an exclusive license from Cal Tech on this technology. Cal Tech licensed
this technology to ABI with the stipulation that ABI would sublicense it on terms
Cal Tech considered reasonable.
B. Issues in the Post-Genomic Era
Changes in the USPTO guidelines on utility requirements, and the adoption
of stricter standards by courts, have curtailed the early rush of patents for Express
Sequence Tags (ESTs) and Single Nucleotide Polymorphisms (SNPs)." However,
concerns still persist. To illustrate, shortly after the SARS outbreak in 2003, patent
applications covering the sequences of the SARS corona virus were filed by several
research teams around the globe. Concerns were expressed that this may give rise
to a complex and uncertain IP situation that could delay the development of the
SARS vaccine."
C. Issues of Access
Genetic testing tools have been widely patented. A study conducted by the
Organization for Economic Cooperation and Development (OECD) 20 on the
licensing practices of holders of patents on the diagnosis of genetic disorders,

16. Id. There is also the consequent reduction in the total royalty stream for the company
itself.
17. J.P. Walsh et al., Research Tool Patentingan2iBiomedicalInnovation in PATENTS INKNOWLEDGE
BASED EcoNoMY (2003).
18.

SNPs are points in the genetic sequence where one person's DNA differs from another's.

These sequences can be used to identify particular genetic conditions.
19. A. Krattinger & S.P Kowalski, FacilitatingAssemblyofandAccessto Intellectual Property:
Focus on Patent Pools and a Review of Other Mechanisms in INTELLECTUAL PROPERTY
MANAGEMENT IN HEALTH AND ARCcuLTURAL INNOVATION:

A HANDnooK OF BEST PRACTICES

(A. Krattiger et al. eds., 2007).
20. OECD, Genetic Inventions, Intellectual Property Rights Licences and Practices:Evidence
and Policies, available at http://www.oecd.org/dataoecd/ 42/21/ 2491084. pdf.
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showed that almost all the patents were being licensed exclusively, thus raising
issues of access to such tools. The following two examples are illustrative.
Canavan's disease: Canavan's disease is a rare and fatal genetic disorder, in
which the myelin sheathing of nerves in the central nervous system degenerates
in infants? In order to study the disease, and develop a screening test for the gene
that gives rise to it, a group of families co-operated with researchers by donating
tissue samples from their children. In 1997, scientists at Miami Children's Hospital
(MCH) received a patent on the method of diagnosis, which also covered therapies
potentially arising from the test. MCH subsequently sought to license the test
exclusively, prompting some clinical laboratories to stop offering the test, and
potentially impeding research on the disease. The parents of the affected families
argued that the test should have been offered non-exclusively and free of charge.
In response to the criticism, MCH halved its per-test fee?
Myriad Genetics: A researcher at the University of Utah found that the
mutation of two genes, BRCA1 and BRCA2, is involved in 5-10% of breast cancer
cases. Women with these gene mutations are seven times more likely to develop
breast cancer than the general female population. Myriad Genetics, a private sector
corporation, holds the patents to the diagnostic tests for BRCA1 and BRCA2.
Myriad's licensing strategy has met with strong opposition? The company insists
that all testing worldwide be performed by Myriad's own laboratories. However,
its charge per test, in many cases, is over US$ 2,500. Many healthcare authorities
and providers believe that the terms of access to this technology are too stringent,
that the costs are too high, and that they may constitute an abuse of monopoly
power.
D. Patent Thickets
The notion of cumulative innovation - each discovery building on many
previous findings - is central to the scientific method? In biotechnology, this is
21. Id.
22. OECD, supra note 20.

23. The reaction worldwide was swift. In France, the Institut Curie, theAssistancePublique
and the Gustave Roussy Institute filed oppositions to the European patents. The Belgian
Society for Human Genetics and the Danish Society for Medical Genetics filed separate
oppositions. In the United Kingdom, negotiations are ongoingbetween the Department
of Health and Myriad regarding the terms of the provision of testing for BRCA1. All
Canadian provinces but one, are ignoring Myriad's injunctions to stop offering breast
cancer genetic testing, despite Myriad's Canadian patents.
24. C. Shapiro, Navigating the PatentThicket: Cross Licenses, PatentPools,and Standard Setting,

availableat http:11faculty.haas.berkeley.edu/shapito/thicket. pdf.
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even more so. Encumbrances of patents on research tools used in an invention can
necessitate negotiating multiple licenses when developing a single product or
process. The term'patent thicket' refers to the dense web of overlapping intellectual
property rights that a company must make its way through, in order to connercialise
a new technology.u Such 'patent thickets' have the potential to raise the transaction
costs of conducting research, and possibly the ultimate cost of products, owing to
stacking of royalties. For example, the development of a medicine may require
licenses to access genomics technologies, such as receptors, assays and highthroughput technologies. Companies report that royalty exposure to net sales price
of a given product can exceed 20% in some cases?6 As more and more biotechnology
companies commercialise research tools'- genomics sequencing and expression
technologies, targets, screening assays, etc. - the pharmaceutical companies that
develop end products must enter into multiple licensing agreements and agree to
thepayment of royalties to many parties, leading to the problem of royalty stacking."
The number of patents required to be licensed for a malaria vaccine,
relying on the MSP-1 protein of the malaria parasite, is illustrative of the thickets
problem. A study mapped close to 401 relevant patents, which included five core
U.S. patents relating to MSP-1, a dozen patents useful in constructing vaccines,
and five specialised patents for the production of MSP-1 vaccines?
The celebrated illustration of the thicket problem in agricultural
biotechnology is the case of Golden Rice, or beta carotene enhanced rice.? Three
genes were inserted into the rice plant to complete the beta-carotene biosynthetic
pathway. In addition to the proprietary genes, the methodology involved the use
of a number of plant transformation vectors, promoters and antibiotic resistance
markers, all of which are the subject of patents held by various owners, or covered
by MTAs. Cumulatively, over 70 patents, held by a dozen or so patentees, were
identified as posing potential licensing issues.?

25. Id.
26. OECD, supra note 20, at 15, quoting Signals Magazine. Royalty exposure to net sales
means the percentage of net sales on a product that must be paid in royalties to the
licensors of technologies used in the development of an end product.
27. Id. at 61.
28. OECD, supra note 20, at 15.
29. The beta carotene in Golden Rice provides dietary VitaninA, intended to cater to the
nutritional needs of peoples for whom rice is the most basic food crop, yet suffer from
Vitamin A deficiency. See R. DAvro ET AL., THE INTELLECTUAL AND TECHNICAL PROPERTY
COMPONENTS OF PRO-VrrAMIN A Rics (GOLDEN RicE): A PRELIMINARY FREEDOM TO OPERATE
REviw, ISAAA BasEs No.20 (2000).

30.

Id.
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Restricted access to upstream technology is a greater concern in the context
of downstream research activity. Some of these patents can pre-empt important
areas of medical research, and act as legal barriers to the development of a broad
category of products. This possibility is particularly strong in the field of
biotechnology for several reasons. First, there are many broadly relevant patents.
Further, research builds on the use of prior technologies, and solid and clear title
to a product is important in the pharmaceutical industry3' A researcher must
therefore redesign a research program in order to avoid using patented techniques,
or obtain licenses from all patent holders.
i. AgriculturalResearch
The institutional context of agricultural biotechnological research differs
from that of biomedical research. The size of the sector and the potential commercial
market are much smaller than in the case of medicine. Traditionally, in agricultural
research, the public sector carried research right to the farm, whereas, in medicine,
commercialisation is an overwhelmingly private sector activity. This landscape is
changing.
Traditionally, discoveries in public research institutions and agricultural
universities were treated as public goods that flowed freely to farmers and
businesses, often through university extension services. This system supported
generations of improvements to crop germplasm. Companies adopted and
improved upon discoveries from public sector institutions, and turned them
into crop varieties for commercial markets. This helped develop a robust seed
industry in developed countries and significantly increase food production in
developing countries.-"
However, the biotechnology revolution and the spread of gene patenting
changed this scenario. Today, the biotechnology industry is dominated by the
private sector. Technology ownership is frequently fragmented between many
owners, resulting in encumbrances on the freedom to operate with select
technologies. This has forced companies to cross-license technologies, and has led
to mergers and acquisitions becoming a means of accumulating portfolios of
agricultural patents, and material, such as germplasm. Today, agricultural research,
at least in the developed countries, is dominated by a few large companies that
control a large proportion of the cutting edge agricultural IP.

31. J.H. Barton, Research-tool Patents: Issues for Health in the Developing World, 80(2) BULL.
WORLD HEALTH ORGAN.

122 (2002).

32. http:I/www.pipra.org/en/about.en.html.
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Many of the enabling technologies required to carry out agricultural research
are patented, and there are concerns on the freedom to operate with technologies,
even in India, as many of our institutions carry out research in agricultural biotech.3
A recent study has suggested that access issues are more serious in agricultural
biotechnology than in biomedicals? The study found that in agbiotech research,
one quarter of the respondents reported that, in problematic cases, a project or
line of research that was part of a project had to be abandoned, or not initiated,
due to lack of access to research tools? 5
Freedom to operate with technologies relevant to research, which leads to
increased food production, is significant in the context of developing countries,
where agricultural research is still mostly carried out by public sector institutions.
If technology induction is a critical component of ushering in a second green
revolution, exceptions which facilitate research with patented research tools and
enabling technologies will have to be made available to scientists.
ii. Other EmergingTechnologies
Early assessments of nanotech patent trends indicate that though the
technology is still in its infancy, patent thickets on foundational nano scale particles,
tools and processes are already creating barriers to would-be innovators? As a
single nano scale application can be relevant for widely divergent applications,
across multiple industry sectors, analysts warn that IP roadblocks could severely
retard the development of nanotechnology?
The repercussions are felt in stem cell research also. An example is the basic

patent involved in the Cellpro case. The discovery made at Johns Hopkins
University was of an antibody that selectively binds to an antigen, CD34, found in
stem cells. The patent was awarded to Johns Hopkins, having claim on all antibodies
that recognise CD34. This patent was licensed to Baxter, which could prevent rival
Cellpro's use of the technology 8
33. For a more detailed discussion, see Z. Thomas, AgriculturalBiotechnology and Proprietary
Rights; Challengesand Policy Options, 8 J. oF Woa. INTELL. PRoP. 711 (2005).
34. B. Wright and P. Pardey, Changing Intellectual Property Regimes: Implications for
Developing CountryAgriculture, 2 INT. J. OF TECH. AND Gn. 93 (2006).
35. Ibid. at 102; L. Zhen et al, Implications of Intellectual Property Protectionfor Academic
Agricultural Biologists, DEPARTMENT OF AcRICULTURAL AND RESOURCE EcoNoMIcs, UC
BERKELEY, available at http://www.are.berkeley. edu/-wright/IJTGWPl.pdf.
36. H. Shand & K.J. Wetter, Trends in Intellectual Propertyand Nanotechnology: Implications
for the Global South, 12 J.OF INTELL. PRoP. R. 111 (2007).

37. bid. at 113.
38. Walsh et al., supranote 17.
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IL PART B
A. Putting TRIPS in Context
Under Article 30, the TRIPS Agreement allows the use of limited exceptions
to the exclusive rights granted by a patentY"This provision is reflected in many
national legislations in the form of research exceptions. Article 31 of the TRIPS
Agreement permits compulsory licensing and government use, without the
authorisation of the right-holder, subject to conditions aimed at protecting the
legitimate interests of the right-holder. These conditions include the obligation
not to grant such licenses as a general rule, unless an unsuccessful attempt has
been made to acquire a voluntary license, on reasonable terms and conditions,
and within a reasonable time period. A compulsory license can be issued to permit
exploitation of a patent, which cannot be exploited without infringing another
patent. The grant is subject to the requirement of paying an adequate license fee.
Such license must be predominantly for the domestic market."
i. Compulsory Licenses
Patent laws of most countries allow governments to issue compulsory
licenses on various grounds. The U.K. Patent Act confers such extensive powers,
though they are rarely exercised . The United States patent statute does not contain
any provision for compulsory licensing. But 35 USC § 203 provides for march-in
rights, as part of the Bayh-Dole amendments, where federal funding of an invention
is involved.
Section 84 of the Indian Patents Act, 1970 permits the grant of compulsory
licenses where (a) the reasonable requirements of the public, with respect to the
patented invention, have not been satisfied, or (b) the patented invention is not

39. Members may provide limited exceptions to the exclusive rights conferred by a patent,
provided that such exceptions do not unreasonably conflict with the normal
exploitation of the patent, and do not unreasonably prejudice the legitimate interests
of the patent holder, taking into account legitimate interests of the third parties.
40. The Doha Declaration clarified the compulsory licensing provision to enable members
in taking measures to protect public health. It makes it clear that each member-state is
free to determine the grounds upon which compulsory licenses are granted, In
conditions of national emergency the usual stipulation that an effort must be made to
seek voluntary license would not apply.
41. Section 48(1) of the UK Patent Act allows issuance of compulsory licenses in the event
of "refusal of the proprietor of the patent to grant a license on reasonable terms.. .the
exploitation -of any patented invention which involves an important technical advance of
considerableeconomic significance in relationto the inventionfor which the patent concerned

was granted is prevented or hindered". C. Clift, supra note 5 at 84.
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available to the public at a reasonable price, or (c) the patented invention is not
worked in the territory of India. But such licenses can be issued only after three
years have expired from the date of grant of the patent This limits the use of
such provisions for research tools since the latest research tools may be required
for cutting edge research.
The conditions and stipulations attached to the grant of compulsory licenses,
and the procedure prescribed for obtaining such license, are likely to make the
procedure lengthy. Where multiple patents are involved, requiring multiple
licenses, the compulsory license provision is unlikely to be of immediate help to
researchers.

ii. Research Exceptions
Patent laws around the world permit some form of research exceptions.
The law relating to research exceptions in some major jurisdictions is discussed
below.

a. United Kingdom
In the U.K., the Patent Act exempts acts done privately for noncommercial purposes and acts covering an experimental purpose relating to
the invention. The cases that discuss the private purpose exemption include
Smith Kline and French Laboratories Ltd v. Evans Medical,44 and McDonald
42.

See also Section 89 which mandates, inter alia, that the powers under Section 84 should

be exercised to protect the interest of any person for working or developing an
invention under the protection of patent are unfairly prejudiced. Section 91 on licensing
of related patents enables grant of compulsory license to work any other patented
invention could aid researchers.
43. The statutory exemptions for patent infringement that might be of relevance to early
stage bio-medical and biotechnological research are contained in the UK Patents Act
in Sections 60(5), (a)-(c):
60(5). An act which, apart from this subsection, would constitute an infringement of
a patent for an invention shall not do so if:
(a) it is done privately and for purposes which are not commercial;
(b) it is done for experimental purposes relating to the subject-matter of the invention;
(c) it consists of the extemporaneous preparation in a pharmacy of a medicine for an
individual in accordance with a prescription given by a registered medical or dental
practitioner or consists of dealing with a medicine so prepared. See F. Bor, Exemptions
to Patent Infingement Applied to Biotechnology Research Tools, 28(1) E.I.RR. 5 (2006).
44.

Smith Kline and French Laboratories Ltd v. Evans Medical, [1989] F.S.R. 513. The

Court held that an act will be exempt if it clears a two-stage test involving; (1)
determining whether an act is private or public; and (2) determining whether the act
has or has not been carried out for commercial purposes. See Bor, supra note 43.
191
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v. Graham. 45The court, in Smith Kline and French Laboratories Ltd, held that the
private purpose exemption relates essentially to an individual carrying out scientific
experiments at home, with no commercial goal in mind, and does not cover any
acts carried out for commercial purposes.' But the acts done for experimental
purposes, relating to the subject-matter of the invention, even if for commercial
purposes, are exempt.4
b. European Union
Research exemptions have been incorporated into Art, 31(b) of the European
Community Patent Convention, and have been transposed into the patent laws of
many European countries.4 In most of Europe, exceptions exist for acts performed
privately, for purposes that are non-commercial, and for experimentation on the subject
matter of invention, even if for commercial purposes.4" In most of Europe, the
experimental user right guarantees the freedom, to all skilled in the art, to test and
examine patented inventions, without the consent of the patent owner even during
the term of protection, in order to establish the invention's utility working advantages
and disadvantages, and above all, to develop, on the basis of the knowledge so acquired,
improved (patent-dependent) or new (patent-independent) solutions?
c. United States

In the United States, there is no statutory exception for research uses. But
United States Patent law provides for a safe harbour for drug development through
an FDA exception, in 35 USC § 271(e)(1).5
The common law research exception in the United States has its origins in
the 19* century case of Whittemore v. Cutter,' wherein the exception was limited
45.
46.
47.
48.

McDonald v. Graham, [19941 R.P.C. 407.
Bor, supra note 43.
Bor, supra note 43.
For example, Section 60(5) of the UK Patents Act, and Section II of the German Patent
Law, 1981. See Bor, supra note 43.

49. Clift, supra note 5.
50. Bor, supra note 43, at 6, quoting Professor Joseph Straus, the managing director of the
51.

Max Planck Institute for Comparative Research in Patent Law.
35 U.S.C. § 271(e)(1) states:
It shall not be an act of infringement to make, use, offer to sell, or sell within
the United States, or import into the United States, a patented invention....
solely for uses reasonably related to the development and submission of
information under a Federal law which regulates the manufacture, use, or
sale of drugs or veterinary biological products.

52. Whittemore v. Cutter, 29 F. Ca. 1120 (C.C.D. Mass. 1813); Bor, supra note 43.
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to philosophical experiments with the patented invention. But the ruling in Madey
v. Duke University casts considerable doubt on educational use exceptions, if the
use has the slightest commercial implicationY This ruling had cast doubt on the
availability of the common law experimental exception,' but recent decisions seem
to show that the exception survives. In Merck v. Integra Life Sciences,55 the U.S.
Supreme Court, overturning a plea for a restricted reading, ruled that section
271(e)(1) "exemptedftom infringement,all uses ofpatented compounds 'reasonablyrelated'
to the process of developing informationfor submission" to the FDA." In the 2007 ruling
by the Federal Circuit in Integra Life Sciences v. Merck KGaA,57 the court discussed
the experimental use exception claimed by the defendant, which had been allowed
by the District Court. But this was not the subject matter of appeal.58 Merck did not
rely on the common law experimental use defence, and, in fact, counsel for Merck
stated that this defence was not applicable to this case. The natural presumption is
that the common law research exception for basic scientific research survives.
Experts conclude from the approach adopted by the US courts that it is
apparent that the courts will enjoin the use of infringing research tools only to prevent
future infringement and that past infringement may be remedied only by an award
of damages."9 The award of damages itself may be treated as an implied license to
use the research tool, precluding injunctive relief. Damages on research tool patents
53.

Madey v. Duke University, 307 F 3d 17T The Federal Circuit ruled that regardless of

whether a particular institution is engaged in an endeavour for commercial gain, so
long as the act is in furtherance of an alleged infringer's legitimate business, and is
not solely for amusement, or to satisfy idle curiosity or for strictly philosophical
enquiry, the act does not qualify for the narrow and strictly interpreted experimental

use defence.
54. "In light of the Madey decision, which instituted the death of the common lat research
exemptionfor all practicalpurposes, scholarsare taking a closer look at how research toolsfit
into the overall picture ofpatentpolicy." See M.D. Walker, The PatentResearch tool Problem
after Merck v. Integra, 14 TEx. INTELL. PROP. L.J. 1, 30 (2005).
55. Merck KGaA v. Integra Life Sciences Ltd., 545 U.S. 193.
56.
57.

Ibid. at 206.
Integra Life Sciences v. Merck KGaA, Fed. Cir., 2002-1052,-1065.

58. Integra Life Sciences, Fed. Cir., 2002-1052,1065. The District Court ruled that all but
one of the initial studies of angiogenesis inhibition by the first cyclic RGD peptide
were of the nature of basic scientific research and within the common law research
exemption. No appeal was taken from this ruling, and these early experiments are
not included in the subject matter charged with infringement. Although, in the District
Court, the defendants had argued that at least some of the ensuing studies were also
shielded from infringement by the common law research exemption, this argument
was not presented on appeal to the Federal Circuit or the Supreme Court
59. R.K. Seide & M.M. LeCointe, supra note 6.
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by NIH grants. The guidelines provide that, whenever possible, non-exclusive
licensing should be pursued as best practice. The non-exclusive licensing approach
favours and facilitates making enabling technologies and research tools widely
available and accessible to the scientific community."
The NIH has also been intervening in select cases like that of Harvard
Oncomouse, which contained a recombinant, activated oncogene sequence, that
permitted it to be used for testing early stage anticancer drugs. Harvard had
licensed it to Dupont exclusively. The NIH prevailed upon Dupont to sign a
memorandum of understanding that permitted relatively unencumbered
distribution of the technology from one academic institution to another. 0
The universities in the United States have been at the forefront of conducting
basic research. The approach of the Stanford University in licensing Cohen-Boyer
patents non-exclusively has been widely acclaimed. But it does not seem that many
universities followed the Cohen-Boyer example set early in the industry. The BayhDole Act encourages, and most universities in the U.S. practice the grant of exclusive
licenses on their patented technologies. The consequence of such exclusive licensing
was felt immediately in agricultural biotechnology. Writing in Science, the heads of
12 leading U.S. universities observed that they did not have the rights to enabling
technologies their institutions had invented-' They announced the setting up of
the Public Intellectual Property Resource for Agriculture (PIPRA), which aims to
mitigate problems arising from the fragmentation of proprietary technologies among
different institutions. In their licenses, they systematically retain the rights to use
the technologies for research and development of subsistence and speciality crops.

maintenance, reproduction, and/or distribution of the tool, or because further
research and development is needed to realize the invention's usefulness as a
research tool, licenses should be crafted to fit the circumstances, with the goal
of ensuring widespread and appropriate distribution of the final tool product.
69. http://ott.od.nih.gov/policy/lic-gen.html states:
"PHS encourages licensing policies and strategies that maximize access,
as well as commercial and research utilization of the technology to benefit

public health. For this reason, PHS believes that it is important for funding
recipients, and the intramural technology transfer community, to reserve in
their license agreements the right to use the licensed technologies for their
own research and educational uses, and to allow other institutions to do the
same, consistent with the Research Tools Guidelines."
70. Walsh et al., supra note 17.
71. R.C. Atkinson et al., Public Sector Collaborationfor Agricultural IP Management, 301
(5630)

SCIENCE

174 (2003).
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Also, PIPRA member institutions systematically make their current and future
technologies known to each other, and to the world.?
The experience with impediments to research, posed by exclusive licensing
of patented technologies, seems to have altered the approach of some of the
universities.' Stanford has adopted a licensing policy which enables retention of
rights on the licensed technology for non-profit academic research institutions.74
The University of California retains the right to make use of the licensed invention
for itself, and other non-profit educational and other institutions.75
Another approach has been to adopt the open source model in patenting.
This model licenses patented technologies with an open general license, mandating
that further improvements to the technology be made available on the same terms,
thus seeking to overcome the access issues of fragmented ownership of
technologies. CAMBIA, a non-profit research organisation based in Australia,
working in the field of agricultural biotechnology has prepared a model license
which enables the sharing of improved technologies.76
As a result of the experience with MCH and Canavan's disease, other patient
groups have been more active in obtaining agreements on the terms of their cooperation with researchers. Pseudoxanthomaelasticum is a genetic disorder in which
connective tissues calcify PXE International is a voluntary organisation which funds
72.
73.

http://www.pipra.org/en/about.en.html.
A pivotal catalyst for change in the approach of universities was forced by a student
of Yale Law School (Amy Kopzynski) in early 2001, in connection with the stavudine
vaccine for AIDS, jointly patented by Bristol-Myers Squibb (BMS) and Yale University
(trademarked Zerit by BMS to whom Yale had licensed the patent exclusively). This
vaccine was found to be too expensive for those in the poorest regions of South Africa
and in Sub-Saharan Africa. The protests led Yale and BMS to conclude an agreement
to make this treatment available at no cost in South Africa. See AJ. Stevans, Valuation
and Licensing in Global Health, in INTELLECrUAL PROPERTY MANAGEMENT IN HEALTH AND
AcinutRAL INNOVATION: AHANDROOK OF BEST PRACICEs (A. Krattiger et al. eds., 2007).

74. See Stanford Exclusive License Agreement, available at
http://otl.stanford.edu/industry/documents/revstagmt3-08.pdf. ("Retained Rights:
Stanford retains the right, on behalf of itself, and all other non-profit academic research

institutions, to practice the Licensed Patent and use technology for any non-profit
purpose, including sponsored research and collaborations. Licensee agrees that,
notwithstanding any other provision of this Agreement, it has no right to enforce the
Licensed Patent against any such institution. Stanford and any such other institution

has the right to publish any information included in the Technology or a Licensed
Patent.")
75.

OECD, supra note 20.

76. http://www.cambia.org.
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research and provides support to affected families and supports physicians.?They
created a tissue and blood bank which scientists could access to study this genetic
disorder. Access to the bank was conditional on the signing of a contract, which
included a provision for joint ownership with PXE of any resultant intellectual
property. The PXE gene was jointly patented with the scientists at the University
of Hawaii. The patient group developed this strategy to ensure that future licenses
for any genetic tests will be inexpensive and widely available."
Another approach is the potential use of patent pools, which has been
adopted successfully in the electronics industry." However, an OECD report
observed that the pharmaceutical sector is fundamentally different from the
electronics industry. Universal standards and interoperability are not the norm in
the pharmaceutical sector. Acompany is tightly tied to its IP, which fosters a'bunker
mentality'S The report pointed out that the dominant players may have little
incentive to join the pooL Doubts have also been cast on the interplay of competition
laws and patent pools.
A recent study finds that on average, there are more patents and more patent
holders than before, involved in any commercial invention in biomedicine, and
many of these patents are on research tools." However, despite this increased
complexity, none of the commercially or scientifically promising projects has been
stopped because of Intellectual Property rights on research tools. This is attributed
to the abilities of industrial and university researchers to develop working solutions
that allow their research to proceed, some of which have been narrated above.
Further, changes in the institutional environment, particularly USPTO guidelines
on patenting of genetic inventions, some shifts in the approach of the courts towards
research tool patents, as well as pressure from powerful actors like the NIH, also
appear to have warded off the problem? The study suggested the development
of standard contracts and templates, by institutions like the NIH, to license

technologies. In other words, they recommend a licensing policy that enables access
to research tools from public funded projects.
77. http://www.pxe.org.
78. OECD, supra note 20.
79. U.S.P.T.O., in a 2000 report on patent pools and biotechnology, had suggested the
formation of patent pools in the biotechnology field, which could serve the interests
of both the public and the private sectors. Such pools have worked successfully in the
electronics industry.
801 OECD supra note 20.
81. Walsh et al., supra note 17.
82i

Walsh

et al., supra note 17.
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The Government of India is likely to enact a law to create a uniform legal
framework for government-funded research and to give universities and research
institutions ownership, and patent rights, for their innovations? A Bill has been
drafted on similar lines as the U.S. Bayh-Dole Act.M From what has been reported,
it appears that India is moving in the same direction. As India aspires to be a hub
of biotechnological research, lessons learnt from the American experience are
relevant. Indian institutions may have to formulate appropriate responses so that
research will not be stifled on emerging technologies, and so that publicly funded
research serves its intended purpose. The initiative of the Council for Scientific
and Industrial Research (CSIR), to move to open source drug discovery and open
source pharmacogenomics shows that Indian institutions are alive to this issue
and are responding appropriately.
B. A Legal Challenge
Historically, research or educational exceptions in patent law were
formulated in the 1 9 1h century. One of the philosophical foundations of the patent
law is that it encourages inventors to find alternative ways to achieve the same
end. According to Chisum, one of the objectives of the patent system is to provide
an inducement for inventing around the patents, on successful inventions, to bring
more innovations to the public." By giving protection to existing patents, the patent
system acts as a teaser to an inventive mind to bring about new inventions. Such
new inventions may include new ways of achieving the same result. These may
generally be described as work arounds. The 1 9 1hcentury courts constructed a
narrow exception based on current technologies which enabled such'work around'
inventions. A diversity of similar, but not identical approaches represents the
hallmark of innovation.17 It generates competition, drives innovation and leads to

83. K. Pathak, supra note 3.
84. P.T.J. Datta, PublicFunded Research May Pay Dividendsfor Scientists, BUsINEss LINE (Mar.
17,2008). The Bill encourages public-funded institutes to patent inventions and explore
avenues for commercialisation. It proposes that the inventor gets 30 per cent of the
revenue from commercialising the patent, while 10 per cent is ear-marked for the
institute's IP Management Cell. Rights to the product remain with the institute, while
assignment rights are jointly held between the scientist, the institute and the
government. Commercialisation plans require consent from all the three.
85.

See Interview with Dr. S.K. Brahmachari,DG CSIR, availableat

http://spicyipindia.blogspot.com/search?q=Brahmachari.
86. D. Carsm, PRINcIPLEs OF PATENT LAW: CASES AND MATERIALS (2002).
87. K.N. Cukier, Navigating the Future(s) of Biotech Intellectual Property, 24(3) NATURE
BIOmECoOcY 249 (2006).
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subsequent 'creative destruction' that is the cornerstone of capitalism. The
impossibility of a workaround was never anticipated in patent law."
The courts have traditionally interpreted these exceptions strictly. In the
U.K., courts restricted it to the acts of an individual carrying out research for non-

commercial purposes, while in the U.S. it was limited to the satisfaction of idle
curiosity. The statute in India reflects the traditional strict approach.
This traditional approach creates unique problems in genomics. Genes and
genetic sequences have unique informational content, making it impossible for
researchers to invent around them." For example, genes detecting disease
susceptibility, or encoding therapeutic proteins, are not amenable to workarounds
since substitutes are not possible by nature. 0 Lack of potential for workarounds
represents an enormous problem for the patent system to operate in biotech
research."
Hence, the traditional research exceptions have an inherent inadequacy
to deal with genornic inventions. This lack of workarounds was probably not
contemplated in patent law. Hence, the approach to traditional research
exceptions, based on the classical philosophy behind research exceptions, seems
insufficient to handle the issues posed by genomics. The courts and the policy
makers have to now remodel the exception, which was originally tailored to the
needs of the nineteenth century, to address the challenges posed by

2 11t

century

technologies.
In the Indian context, the provisions of the statute which reflect the
traditional, strict approach to exceptions do seem to require modification in the
context of the challenges posed. Also, Indian scientists do not have the common
law research exceptions available in jurisdictions like the U.S. Viewed in the context
of research exceptions available in the European Union and Japan, there is a case
for modifying the provisions of research exceptions as available in section 47(3) of
the Patent Act.

88.

Id,

89. G. Matthijs, PatentingGenes may Slow Down Innovationand Delay Availability of Cheaper
Genetic Tests, 329 B.M.J. 1359 (2004).
90. Id.

91. Matthijs, supra note 89.
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IV. CONCLUSION
So, is there clear evidence of the anti-commons in research tools thwarting
social welfare? There is little evidence yet. But most commentators agree that the
patenting of research tools has made the research landscape more complex. The
19 h century philosophies of research exceptions in patent law are insufficient to
accommodate the challenges of the nature of science in biotechnology,
nanotechnology or stem-cell research. Appropriate responses are being tailored
by leading players in the field.
As per the Supreme Court of India, the'object of patent law is to encourage
scientific research, new technology and industrial progress'. 2 To meet this objective,
Indian policymakers need to analyse the experiences of the U.S. and other countries,
and frame appropriate responses, both from the legal and policy angles. The
response may be at least two fold. On the legal side, the existing provision on
research exceptions in Indian law is inadequate, as compared to the provisions of
the laws of Europe or Japan. The law may require fine tuning, as India does not
have the common law exception which exists in the United States. Institutions
which are involved in managing and overseeing research may have to formulate
appropriate policies on technology invented with their funds, to retain rights to
use the technology for research and other related purposes, by that institution or
by others, while licensing its technologies.

92. M/s Biswanath Prasad Radhey Shyam v. M/s Hindustan Metal Industries, A.I.R. 1982
S.C. 144.
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